Statement of Principles concerning smallpox (Balance of Probabilities) (No. 6 of 2026)

The instrument establishes a tightly framed set of medical and causal concepts that feed into statutory decision-making under the VEA and MRCA. Primary defined concepts are smallpox, death from smallpox, relevant service, and terminal event.

Smallpox is defined narrowly as a clinical illness caused by infection with the variola virus, confirmed by laboratory testing, and expressly includes both variola major and variola minor (s7(2)). The Statement therefore requires laboratory confirmation as part of the disease definition. The instrument also records the usual clinical picture as an explanatory note, but that clinical description is illustrative: the legal definition for application of the Statement is the laboratory-confirmed variola infection (s7(2) and note).

Death from smallpox is captured not only where death is directly attributed to variola infection but also where death occurs from a terminal event or condition that was contributed to by the person’s smallpox (s7(4)). The Schedule lists examples of terminal events including pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function (Schedule 1 - Dictionary). This expands the causal reach of the Statement to deaths where smallpox was a contributing factor to a terminal event.

Relevant service is defined in the Schedule and is not coextensive with all military service. It comprises eligible war service under the VEA other than operational service, defence service under the VEA other than hazardous service and British nuclear test defence service, and peacetime service under the MRCA (Schedule 1 - Dictionary). The definition therefore excludes certain service categories, for example operational war service and the specified hazardous or British nuclear test defence service, from being “relevant service” for the purposes of this Statement. The effect is that the RMA’s causation templates apply only where the person’s service fits into the categories listed.

Causation is operationalised by a discrete list of factors, any one of which, if it exists and is related to the person’s relevant service, suffices for a connection on the balance of probabilities. Those factors are:

• Direct pathways of exposure to variola virus, including close contact with an infected person; direct contact with body fluids or tissue from an infected person; direct contact with a laboratory strain of variola virus; handling contaminated clothing, bedding or objects; skin penetration by an instrument contaminated with variola virus; or inhaling droplet nuclei or aerosols of variola virus. For these exposure pathways, variola virus exposure must have occurred in the 4 weeks immediately preceding clinical onset (s9(1)(a) and subitems).
• Inability to access appropriate smallpox vaccination in accordance with contemporary medical standards of the time within the 2 years immediately preceding clinical onset (s9(2)).
• Being pregnant within the 6 weeks immediately preceding clinical onset of haemorrhagic type smallpox or death from smallpox (s9(3)).
• Inability to obtain appropriate clinical management for smallpox before clinical worsening (s9(6)).

The Statement is explicit about temporal windows for causation: exposure window 4 weeks, vaccination access window 2 years, pregnancy window 6 weeks for haemorrhagic smallpox. Those windows set the evidential timelines that decision-makers must evaluate.

Finally, the RMA records the evidentiary standard it relied upon in framing the Statement: it is of the view, on sound medical‑scientific evidence, that it is more probable than not that smallpox and death from smallpox can be related to relevant service (s8). The Statement therefore embodies a balance-of-probabilities causal threshold for the particular disease and factors it sets out.

The Statement is directed at veterans and members of the Australian Forces who make claims that fall under section 120B of the VEA or section 339 of the MRCA (Application, s5). It operates as a determinative instrument for decision-makers charged with assessing causation of smallpox and death from smallpox in the context of those statutory claim pathways. The Statement therefore affects the following groups in concrete terms:

• Claimants: veterans or current/former members seeking benefits where smallpox or death from smallpox is claimed to be related to their relevant service. Those claimants must fit within the prescribed definition of “relevant service” in the Schedule. Relevant service comprises eligible war service (other than operational service), defence service (other than hazardous service and British nuclear test defence service) under the VEA, and peacetime service under the MRCA (Schedule 1 - Dictionary). If a person’s service is operational, hazardous, or a British nuclear test defence service, that service category is excluded from the Statement’s relevant service definition and therefore the Statement will not apply to claims based on those categories.
• Decision-makers and adjudicators under the VEA and MRCA: they must apply the causation framework set out in this Statement in determining whether a person’s smallpox or death from smallpox is connected with their relevant service. The Statement provides the lists of qualifying factors and temporal thresholds that adjudicators should use when testing causation on the balance of probabilities.
• Medical officers and expert witnesses providing evidence to claims: the Statement enjoins a laboratory-confirmed definition of variola infection (s7(2)), which focuses expert evidence on laboratory testing, exposure pathway, timing relative to clinical onset, vaccination history and access, pregnancy status, and adequacy of clinical management prior to worsening.
• Administrators of other Statements of Principles: where one of this Statement’s factors refers to an injury or disease that is the subject of another Statement made under subsection 196B(3) of the VEA, that other Statement applies as in force from time to time (s11). This dynamic cross-reference means administrators and claimants must be alert to changes in other Statements that intersect with the factors here.

The instrument also has indirect effects on record-keeping and evidential behaviour. Because the Statement requires laboratory confirmation of variola infection and specific timing windows for exposure, vaccination access and pregnancy, affected persons and their advisers will need to produce contemporaneous medical records, laboratory reports and service records to support temporal links to relevant service. The Statement does not create new obligations for other agencies to hold records, but it sets evidential thresholds that make availability and quality of records consequential to the outcome of claims.

Finally, the repeal of the 2016 Statement (s4) means that decision-makers and claimants must use this 2026 Statement for claims falling within the stated application. The text does not itself specify transitional arrangements for claims in progress; it simply repeals the prior instrument and replaces it with this new Statement.

This instrument does not create statutory duties or rights in the form of civil obligations or criminal offences. Instead it prescribes the RMA’s authoritative causation template to be used in deciding whether smallpox or death from smallpox is connected with a person’s relevant service for claims under specified provisions of the VEA and MRCA. That template imposes practical duties on claimants and on decision-makers.

Duties and evidential obligations on claimants and their representatives

• Provide laboratory confirmation. Smallpox for the purposes of this Statement is a clinical illness caused by variola virus confirmed by laboratory testing. The RMA’s legal definition requires laboratory confirmation (s7(2)). Claimants therefore have the practical duty of adducing relevant laboratory reports or credible medical records confirming a variola diagnosis.
• Establish existence of at least one listed factor. The Statement is explicit that at least one of the factors listed in section 9 must exist before it can be said, on the balance of probabilities, that smallpox or death from smallpox is connected with a person’s relevant service (s9 introductory text). That means claimants must compile evidence for at least one factor: exposure within 4 weeks of clinical onset, inability to access vaccination within 2 years prior, pregnancy within 6 weeks prior to onset of haemorrhagic smallpox, or inability to obtain clinical management before clinical worsening (s9(1)-(6)).
• Link the factor to relevant service. Any factor relied upon must be related to the person’s relevant service (Relationship to service, s10(1)). Establishing that relationship is a factual task for the claimant and will typically require service records, duty rosters, deployment histories, laboratory assignment records, or contemporaneous medical notes linking exposure or lack of vaccination to the period and circumstances of service.
• Demonstrate temporal criteria. The Statement sets explicit time windows: exposure must have occurred within 4 weeks of clinical onset (s9(1) and subitems); inability to access appropriate vaccination is judged against the 2 years immediately preceding clinical onset (s9(2)); pregnancy timing is the 6 weeks immediately preceding clinical onset for haemorrhagic smallpox (s9(3)); inability to obtain appropriate clinical management applies before clinical worsening, though the Statement does not specify a fixed temporal window for this factor (s9(6)). Claimants must produce date-stamped medical and service records aligned with those windows.

Duties and decision-making responsibilities of decision-makers

• Apply the Statement as the causation template for claims under the cited statutory provisions. Because the Statement is made under subsection 196B(3) VEA, decision-makers must apply it when determining connection under the relevant provisions of the VEA and MRCA (Authority, s3; Application, s5).
• Assess whether the factor(s) exist and are related to relevant service on the balance of probabilities. The RMA states its view that it is of the opinion, on the balance of probabilities, that smallpox can be related to relevant service (s8). That evidential threshold governs how the factors in s9 are used in adjudication.
• Consider cross‑referenced Statements. If any factor in s9 refers to an injury or disease covered by another Statement determined under subsection 196B(3), the decision-maker must apply that other Statement in accordance with its terms as in force (s11).

Rights preserved for claimants

• To have a claim assessed using the RMA’s current Statement of Principles for smallpox. The instrument is the operative Statement from 19 January 2026 (s2) and, subject to the VEA and MRCA procedures, claimants have the right to have their claims determined against it for applicable claims (s5).
• To rely on other Statements where a factor refers to another disease covered by a separate Statement; those Statements apply as in force (s11). That preserves a claimant’s access to cross‑instrument causation pathways where applicable.

Limitations on duties and rights

• The Statement limits its scope to persons whose service falls within the Schedule’s definition of “relevant service.” If a person’s service does not fall within that definition the Statement does not govern causation for them (Schedule 1 - Dictionary).
• The Statement imposes technical evidential requirements such as laboratory confirmation, specific exposure pathways and timing windows. The absence of required documentary evidence will make it harder for claimants to discharge the practical duties implied by the instrument.

In short, the instrument creates a legal template that transforms medical and factual circumstances into a determinate list of factors and temporal tests which claimants must meet and decision-makers must apply to establish a service connection for smallpox or death from smallpox.

The Statement of Principles itself contains no express penalties, enforcement mechanisms or compliance sanctions. It is not an enforcement regulation that imposes civil or criminal penalties on third parties. Its legal effect is to operate as a determinative instrument under subsection 196B(3) of the VEA that decision-makers must use when assessing causation for relevant claims (Authority, s3; Application, s5).

How enforcement and effects materialise in practice

• Administrative effect, not direct sanction. The Statement is an administrative and evidentiary tool for use in adjudication of claims under the VEA and MRCA. Its enforcement mechanism is the statutory decision-making process under those Acts: adjudicators will accept or reject a claimant’s assertion that smallpox is connected to relevant service based on whether the factors listed in s9 exist, are related to relevant service and meet the temporal tests. The Statement therefore indirectly affects entitlement outcomes, such as access to benefits or compensation under the VEA or MRCA, but it does not itself prescribe those benefits or their enforcement.
• Repeal consequence. The instrument repeals the prior 2016 Statement (s4). For claimants and agencies, the practical enforcement impact is that the 2026 Statement is the operative causation instrument from its commencement date; decision-makers must apply the new text when determining claims to which the Statement applies. The text does not set out transitional arrangements or savings for determinations made under the 2016 Statement, so the effective enforcement change is that the new rules apply to decisions made after commencement.
• Judicial review and appeal. The instrument does not specify avenues of appeal or judicial review. Any challenge to a decisions applying the Statement would occur under the remedies available within the VEA/MRCA decision framework and the general administrative law regime. The instrument itself does not create a bespoke enforcement or appeal structure.

Practical enforcement considerations and risk areas

• Evidence sufficiency as gatekeeper. Because the Statement requires laboratory confirmation (s7(2)) and sets specific exposure and timing thresholds (s9), adjudicators will be enforcing those evidential gates when determining whether a service connection exists. Failure to produce required laboratory findings or to align factual evidence with the stated time windows will be treated as an evidentiary deficiency rather than as a separate penalty.
• Discretion in assessing the “inability” factors. The Statement uses terms such as “inability to access the appropriate smallpox vaccination in accordance with contemporary medical standards of the time” (s9(2)) and “inability to obtain appropriate clinical management for smallpox before clinical worsening” (s9(6)). Assessment of what counts as inability, contemporaneous standards, or appropriate clinical management will be fact‑sensitive and involve administrative judgement. Those judgments are susceptible to challenge under general administrative law if a claimant alleges the decision-maker misapplied legal standards, but the Statement itself does not create a penalty regime around those assessments.

In summary, enforcement lies in the hands of adjudicators applying the Statement to claims under the VEA and MRCA. The instrument shapes entitlement outcomes by setting the causation rules and evidentiary gates, but it does not itself institute penalties or an enforcement bureaucracy separate to the existing statutory claim processes.

This Statement is a statutory instrument made under subsection 196B(3) of the VEA and is intended to be used in the statutory decision-making context of the VEA and the MRCA. The instrument therefore interacts with the legislative framework of those Acts and with other Statements of Principles made under the VEA. The instrument’s text sets explicit cross-references and internal limits that define these interactions.

Primary statutory interactions

• VEA and MRCA claim frameworks. The Statement applies to claims to which section 120B of the VEA or section 339 of the MRCA apply (Application, s5). It is therefore a component of the causal determination process embedded in those provisions. The Statement does not itself define entitlements under the VEA or MRCA; it informs how causation is assessed when adjudicating entitlements under those Acts.
• Instrument-making power under subsection 196B(3) VEA. The RMA made the Statement under the power in subsection 196B(3) of the VEA (Authority, s3). That statutory source governs the legal status of the Statement and its use by decision-makers. The Statement is thus an instance of the RMA exercising its legislated standard-setting function in respect of medical causation for veterans’ claims.

Cross-references to other Statements of Principles

• Where one of the factors in s9 refers to an injury or disease that is itself the subject of another Statement of Principles under subsection 196B(3) of the VEA, that other Statement applies per its own terms as in force from time to time (s11). This creates a dynamic interaction: if a factor in this Statement involves a condition covered by another Statement, adjudicators must consult and apply that other Statement. Because s11 ties application to the other Statement “as in force from time to time,” decisions may be affected by later amendments to those other Statements.

Interaction with classification codes and clinical standards

• ICD‑10‑AM reference. The instrument notes that smallpox attracts ICD‑10‑AM code B03 but specifies that, for application of the Statement, the legal meaning of smallpox is the laboratory-confirmation definition in s7(2) rather than the coding alone (s7(5) and note). The instrument also clarifies which edition of the ICD‑10‑AM is referred to in the note, giving the Tenth Edition effective 1 July 2017 as the reference point for code naming only (s7(6)). This indicates that medical coding is informative but subordinate to the statutory definition.
• Contemporary medical standards. The vaccination-related factor requires assessment against “contemporary medical standards of the time” (s9(2)). That phrase imports an external clinical standard into the statutory test and requires decision-makers to assess availability and appropriateness of vaccination relative to prevailing medical standards at the relevant time. Interaction will therefore occur with historical clinical guidelines, public health policies, and professional standards contemporaneous with the claimed period.

Scope limits embedded in definitions

• “Relevant service” definition narrows interaction with other service-based legislation. The Schedule defines “relevant service” narrowly to include certain VEA and MRCA service categories and to exclude others (Schedule 1 - Dictionary). This limits the Statement’s interaction to claims stemming from the specified categories and leaves claims arising from excluded service categories to be considered under other applicable legal instruments or frameworks.

Transitional and consequential interactions

• Repeal of earlier Statement. The 2016 Statement is repealed by s4. For decision-makers and claimants, that produces a switch in the operative causation rules. The Statement itself does not set transitional rules, so interaction with prior determinations, ongoing appeals, or pending claims will occur according to the VEA and MRCA decision procedures and any general administrative law principles regarding retrospective application of new policy instruments.

In sum, the Statement interacts with the VEA and MRCA adjudicative frameworks by providing the causation template for smallpox-related claims, cross-references other Statements when factors overlap, requires assessment against contemporaneous medical standards, and limits its own reach by a defined notion of relevant service.

The instrument records a direct repeal and replacement relationship with the prior RMA Statement on smallpox. The text explicitly repeals the Statement of Principles concerning smallpox (Balance of Probabilities) (No. 90 of 2016) (Federal Register of Legislation No. F2016L01670) (Repeal, s4). That is the single express amendment history item contained within the instrument.

Chronology in the instrument

• Date of instrument: The instrument is dated 19 December 2025 on its face (front matter). It commences on 19 January 2026 (Commencement, s2).
• Repeal of 2016 Statement: Section 4 effects repeal of the prior instrument identified by instrument number and year. The new Statement therefore supersedes the 2016 Statement from its commencement date.

What the instrument does not do on amendment history

• No partial repeal or modification clauses are present. The instrument does not preserve any parts of the 2016 Statement; it expressly repeals it in full (s4).
• No transitional or savings provisions are included. The text contains no clause specifying whether decisions already made under the 2016 Statement remain valid, whether ongoing claims are to be processed under the earlier or later Statement, or whether evidence that satisfied the prior Statement will remain satisfactory under the new Statement. The absence of explicit transitional provisions means that transitional handling must be governed by the VEA and MRCA procedural rules and by general administrative practice.
• No history of intermediate amendments recorded in this instrument. The instrument does not itself summarise any intervening amendments between 2016 and 2026; it simply repeals the earlier instrument.

Practical consequence of the stated amendment history

• The repeal is straightforward: adjudicators, claimants and advisers must apply the 2026 Statement for causation issues concerning smallpox for claims within the instrument’s application from 19 January 2026 (s2, s4, s5). Parties handling claims straddling the commencement date need to be mindful that the causation template has changed and must check which Statement is to be applied in their particular administrative or legal context, using the VEA/MRCA rules and any relevant administrative guidance.

No other amendment or historical information appears in the text. The Statement provides no legislative history, explanatory memorandum or ministerial statement within its text; the only explicit historical act recorded is the repeal of the 2016 Statement.

The instrument itself does not record any litigation history. It contains no citations to cases, judicial determinations, or administrative appeals. There are no named decisions, no description of prior legal contestation of the 2016 Statement or its application, and no mention of litigation arising from the repeal. The only legal reference is to the statutory basis for the RMA’s instrument-making power, namely subsection 196B(3) of the VEA (Authority, s3).

Implications for practitioners

• Absence of recorded litigation in the instrument means that any legal understanding of how courts or tribunals have interpreted similar Statements must be found outside the instrument. This document does not supply case law or precedent analysis.
• Where parties wish to challenge how decision-makers apply this Statement in a particular claim, the available avenues will be those provided by the VEA/MRCA decision-making and review processes, and if necessary, general administrative law remedies. The instrument itself does not elaborate on review mechanisms.
• Because s11 provides for other Statements to be applied “as in force from time to time,” any litigation about conflicting or changing Statements will depend on the interaction of multiple instruments and the facts of particular claims. The Statement does not provide guidance on resolving conflicts between Statements beyond instructing that the other Statement applies in accordance with its terms.

For the purposes of advising clients, practitioners will need to search VEA/MRCA case decisions, Veterans’ Review Board decisions, Administrative Appeals Tribunal decisions, and any judicial review judgments external to this instrument to build a litigation history or precedent-based argument. The Statement provides the statutory template to be argued for or against in those fora, but it contains no internal litigation narrative.

This Statement contains a number of technical features and drafting choices that create tangible evidential and administrative pitfalls for claimants, advisers and decision-makers. These are the concrete “gotchas” to watch for when preparing or deciding claims.

1. Laboratory confirmation requirement as definitional gate

• The Statement defines smallpox as a clinical illness caused by variola virus, confirmed by laboratory testing (s7(2)). That elevates laboratory confirmation from a helpful piece of evidence to a definitional requirement for the disease to be within this Statement. Absent laboratory evidence, an adjudicator may find the legal definition unmet even if clinical notes indicate a classic presentation. The ICD code note clarifies that the B03 code is informative but not dispositive (s7(5) and note).

2. Tight temporal windows for exposure and vaccination

• Exposure factors require that variola virus exposure occur within the 4 weeks immediately preceding clinical onset (s9(1)). This is a short window and will demand precise date evidence for both exposure events and clinical onset.
• Inability to access vaccination is limited to the 2 years immediately preceding clinical onset and must be assessed against “contemporary medical standards of the time” (s9(2)). The phrase “contemporary medical standards of the time” triggers a need to reconstruct historical vaccine availability and standards for the relevant period. That reconstruction is evidentially heavy and may be contested.

3. Pregnancy factor limited to haemorrhagic smallpox and a 6 week window

• The pregnancy factor applies only where the person was pregnant within the 6 weeks immediately preceding clinical onset of haemorrhagic type smallpox or death from smallpox (s9(3)). Two linked constraints are present: first, haemorrhagic type must be the clinical subtype, and second, the pregnancy timing must fall in a narrow six week window. Practitioners must ensure the record supports both elements.

4. “Inability to obtain appropriate clinical management” is vague

• The Statement includes “inability to obtain appropriate clinical management for smallpox before clinical worsening” as a qualifying factor (s9(6)). The phrase leaves unspecified what “appropriate clinical management” is and what time frame counts as “before clinical worsening.” Evaluations will require evidence of available health services at the time, steps taken to seek care, and contemporaneous clinical records showing timing of deterioration. The lack of objective criteria creates a discretionary assessment point.

5. Relationship to relevant service is mandatory and context-specific

• Any factor must be “related to the relevant service rendered by the person” (s10(1)). Because “relevant service” is narrowly defined in the Schedule, there is an immediate risk that a claimant with a classic exposure but outside those categories of service will not qualify under this Statement (Schedule 1 - Dictionary). Also, the Statement states that the clinical worsening aspect of factors applies only where the person’s smallpox was suffered or contracted before or during, but did not arise out of, the person’s relevant service (s10(2)). This nuanced limitation can be a trap if advisers do not carefully map the chronology of onset, service dates and exposure origins.

6. Cross-reference to other Statements can introduce moving parts

• Section 11 requires that where a factor refers to an injury or disease covered by another Statement, the other Statement applies “as in force from time to time” (s11). This means a factor’s legal treatment may change if the other Statement is amended after the event. The dynamic cross-reference creates the possibility that a claim that initially seems supportable may be affected by later changes to different Statements.

7. Repeal of the 2016 Statement without transitional text

• The instrument repeals the 2016 Statement (s4) but contains no transitional provision. That omission may create disputes about which Statement applies to claims that commenced prior to 19 January 2026 but remain undecided after that date. Practitioners should not assume automatic grandfathering.

8. The Statement is limited to specific service categories

• Because “relevant service” excludes operational service and certain hazardous or British nuclear test service categories under the VEA, persons who contracted smallpox in circumstances tied to those excluded categories will not benefit from this Statement’s presumptive causal pathways. Advisers must check service classification carefully (Schedule 1 - Dictionary).

9. Death causation includes contribution to terminal events

• Death from smallpox includes deaths where a terminal event was contributed to by smallpox (s7(4)). Practically, this requires evidence that smallpox materially contributed to the terminal event listed in the Schedule. Establishing contribution to events like pneumonia or respiratory failure will depend on clinical causation opinions and medical records.

10. Evidence collection burden is concentrated on claimants

• The combination of laboratory-confirmation, tight temporal windows and service-relationship requirements concentrates evidential work on claimants. In contexts where records are incomplete or lost, this can result in denial or deferred causation findings, unless substitute evidence can satisfy decision-makers on the balance of probabilities.

Being mindful of these concrete drafting features will help advisers and decision-makers avoid the common procedural and evidential traps embedded in the instrument.

This Statement does not establish administrative obligations on third parties beyond its role in decision-making, but it creates clear practical steps that claimants and their advisers should follow to maximise the chance that a claim will meet the RMA’s causation template. Compliance, in this context, means assembling and presenting evidence that addresses the specific definitional and factorised tests in the Statement.

Stepwise, practical compliance checklist

1. Confirm the claim falls within the Statement’s application

• Verify that the claim is one to which section 120B of the VEA or section 339 of the MRCA applies (Application, s5). Ensure the claimant’s period and type of service are within the Schedule’s definition of “relevant service” (Schedule 1 - Dictionary). If the service is operational, hazardous, or a British nuclear test defence service under the VEA, this Statement will not apply.

2. Establish the disease under the Statement’s definition

• Obtain and provide laboratory confirmation of variola virus infection. The Statement’s legal definition of smallpox requires laboratory confirmation (s7(2)). Provide the exact laboratory test reports, dates of collection, diagnostic criteria used and any microbiology or pathology reports. Clinical notes describing the onset, symptoms and progression should be included, but will not replace the laboratory confirmation requirement.

3. Determine and document clinical onset dates precisely

• The Statement sets precise temporal windows for exposure and other factors. Record the date of clinical onset precisely and corroborate it with medical notes, diaries, duty records or contemporaneous documentation. The exposure window for direct variola exposure is 4 weeks prior to clinical onset (s9(1)). Vaccination-unavailability is assessed against the 2 years immediately preceding clinical onset (s9(2)). For pregnancy-related factors, establish the pregnancy status and the relevant dates within 6 weeks immediately preceding clinical onset of haemorrhagic smallpox (s9(3)).

4. Select and document at least one qualifying factor from s9

• Exposure pathway factors: if claiming exposure, provide evidence of close contact, handling contaminated materials, laboratory strain exposure, skin penetration by contaminated instruments or inhalation of aerosols. Include service rosters, workplace incident reports, witness statements, lab duty logs, infection-control incident notifications, or outbreak reports that link the exposure to the service environment and place it within the 4 week window (s9(1) and subitems).
• Vaccination factor: if relying on inability to access vaccination, document attempts to obtain vaccination, contemporaneous public health policies or vaccine availability records, and any barriers encountered. Because the test is assessed against “contemporary medical standards of the time” (s9(2)), gather relevant clinical guidelines, procurement records, facility vaccination logs, or official public health statements to show lack of access according to prevailing standards.
• Pregnancy factor: if relevant, provide obstetric records, pregnancy test dates and clinical notes showing the pregnancy dates fall within the 6 weeks immediately preceding onset of haemorrhagic smallpox (s9(3)), and show that the clinical presentation was the haemorrhagic type.
• Clinical management factor: if asserting inability to obtain appropriate clinical management before clinical worsening (s9(6)), assemble contemporaneous medical notes showing, for example, attempts to seek care, any triage decisions, transfers declined, lack of access to particular medical interventions, or documentation of health service capacity constraints at the time.

5. Connect the factor to relevant service

• Prepare documentary evidence linking the chosen factor to the person’s relevant service. This may include service records, postings and dates, duty descriptions showing proximity to infected persons or contaminated materials, laboratory assignment records, and incident reports that place the exposure or access failure within the context of service (Relationship to service, s10(1)). If the smallpox was contracted before or during but did not arise out of service and the claim relies on clinical worsening, ensure records show the timing and the material contribution or aggravation of service to the course of disease (s10(2)).

6. If a factor refers to another Statement, consult that Statement

• Where a factor in s9 references an injury or disease covered by a different Statement made under subsection 196B(3), obtain and apply the current text of that other Statement “as in force from time to time” (s11). Ensure the evidence addresses the requirements of both Statements.

7. Assemble corroborating clinical causation opinions

• For death claims or where contribution to a terminal event is alleged, secure medical opinions that explain the causal link between smallpox and the terminal event (s7(4); Schedule 1 - Dictionary). Provide reasoned opinion linking medical findings to smallpox as a contributing cause.

8. Be precise and chronological in submissions

• Because the Statement’s windows are immediate and tightly defined, arrange evidence chronologically and clearly indicate how dates align with the required timeframes. Where documentary proof is unavailable due to the passage of time, provide credible explanatory evidence, sworn witness statements and any contemporaneous indirect records that assist the decision-maker to find facts on the balance of probabilities.

9. Anticipate the need to prove “contemporary medical standards”

• For vaccination access disputes, collect contemporaneous clinical guidelines, vaccine policy documents, procurement logs, communications from health authorities and facility records to show what “contemporary medical standards of the time” required or permitted.

10. Prepare for gaps and substitution evidence

• Where critical records are missing, prepare admissible alternative evidence, including sworn affidavits, corroborative witness testimony, and any administrative logs or third party records that show the service nexus, timing and the attempts to access vaccination or care.

Administrative and advocacy notes for advisers

• Check service classification early: the Schedule’s definition of relevant service will determine whether this Statement applies at all. If it does not, advisers must seek alternative legal bases within the VEA/MRCA frameworks.
• Document every step visibly: decisions hinge on documentary proofs tied to the Statement’s formula. A gap in documentation for a precise 4 week or 2 year window can determine outcomes.
• Consider overlapping Statements: use s11 to identify and import requirements from other Statements where factors overlap. Changes to those Statements may affect ongoing claims due to the “as in force from time to time” wording.

Following these steps aligns the claimant’s evidence with the Statement’s definitional and factual thresholds and places decision-makers in a direct position to apply the RMA’s causation template.